Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$880.83 USD

880.83
1,130,837

-4.72 (-0.53%)

Updated Oct 4, 2024 02:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 View

by Zacks Equity Research

Eli Lilly's (LLY) earnings and sales surpass third-quarter estimates. The company lowers 2022 financial view for the third time this year. The stock falls in pre-market trading.

Pre-Markets in Green to Start a Fresh Month

by Zacks Equity Research

Pre-Markets in Green to Start a Fresh Month

Incyte's (INCY) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Incyte's (INCY) earnings and revenues fall shy of estimates in the third quarter of 2022. The company tightens Jakafi's full-year net product revenue guidance.

Mark Vickery headshot

Pre-Markets Up Ahead of New Fed Hike, Q3 Beats

by Mark Vickery

Big Pharma giants Pfizer (PFE) and Lilly (LLY) posted beats on both top and bottom lines this morning, while J&J (JNJ) is buying Abiomed (ABMD).

Eli Lilly (LLY) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Lilly (LLY) delivered earnings and revenue surprises of 0.51% and 0.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Dow Notches Strongest Month of Trading Since 1976

by Mark Vickery

At +11%, it's the best October on record for the blue-chip index and the strongest single-month of trading since the U.S. Bicentennial.

Drug/Biotech Stocks' Q3 Earnings on Nov 1: PFE, LLY & More

by Zacks Equity Research

Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Nov 1.

Derek Lewis headshot

Eli Lilly Q3 Preview: Can Shares Stay Hot?

by Derek Lewis

LLY shares have been a bright spot in an otherwise dim market in 2022, outperforming the S&P 500 across several timeframes.

AVEO Oncology (AVEO) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

AVEO Oncology's (AVEO) third-quarter earnings is expected to reflect strong Fotivda sales. The company is likely to beat the Zacks Consensus Estimate.

Merck (MRK) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Merck (MRK) delivered earnings and revenue surprises of 10.78% and 6.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed the most recent trading day at $351.31, moving +0.98% from the previous trading session.

Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex Pharmaceuticals' (VRTX) Q3 earnings call, investors' focus will likely be on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.

Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.

Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

The Zacks Analyst Blog Highlights J&J, Roche, Eli Lilly and AbbVie

by Zacks Equity Research

J&J, Roche, Eli Lilly and AbbVie are part of The Zacks top Analyst Blog.

Merck (MRK) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q3 earnings.

    Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    On Novavax's (NVAX) third-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.

    AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    AbbVie (ABBV) third-quarter performance will likely reflect the impact of strong demand for immunology and aesthetics franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.

    Biogen (BIIB) to Report Q3 Earnings: Here's What to Expect

    by Zacks Equity Research

    Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.

      Kinjel Shah headshot

      Pharma Stock Roundup: JNJ Q3 Earnings Beat, RHHBY Sales Weak, LLY, ABBV Ink M&A Deals

      by Kinjel Shah

      J&J (JNJ) beats earnings and sales estimates for the third quarter. Eli Lilly (LLY) and AbbVie (ABBV) announce small acquisitions.

      Sundeep Ganoria headshot

      4 Biotech Stocks Set to Outpace Q3 Earnings Estimates

      by Sundeep Ganoria

      Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.

      Eli Lilly (LLY) to Buy Hearing Loss Gene Therapy Maker Akouos

      by Zacks Equity Research

      Lilly (LLY) is set to acquire all the outstanding shares of Akouos for approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million.

      Akouos (AKUS) Surges on $610M Buyout Deal With Eli Lilly

      by Zacks Equity Research

      Akouos (AKUS) is set to be acquired by Eli Lilly for an aggregate amount of $610 million. The deal is expected to close in the fourth quarter of 2022. Stock up.